

Certificate of Analysis

Blk, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-517, 14-517-K, 14-517M

Parent Lot # 2152754

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal 6His-tagged, recombinant full-length human Blk, expressed in Sf21 insect cells. Purified using Ni²⁺/NTA agarose. Purity 87.4% by SDS-PAGE and Coomassie blue staining. MW = 58.8kDa.

Specific Activity (Parent lot# 2152754): 152U/mg, where one unit of Blk, active activity is defined as 1nmol phosphate incorporated into 0.1mg/ml poly(Glu, Tyr) (4:1) per minute at 30°C with a final ATP concentration of 100µM.

Formulation: 1.81mg/ml of enzyme in 50mM Tris/HCl pH7.5, 150mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 0.2mM PMSF, 1mM benzamidine, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.

**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**


Quality Control Testing

Kinase Assay: 65–181ng of this lot of enzyme phosphorylated 0.1mg/ml poly(Glu, Tyr) (4:1) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed product identity as Blk with the translated sequence listed on page three.

SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3µg of Blk, active.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **10 x Reaction Buffer:** 500mM Tris/HCl pH7.5, 1mM EGTA, 1mM Na₃VO₄, 1% 2-mercaptoethanol.
2. **Poly(Glu, Tyr) (4:1):** Use at a final assay concentration of 0.1mg/ml. Prepare a 1mg/ml stock. Use 2.5µl of stock per assay point.
3. **Blk, active:** Dilute with 50mM Tris/HCl pH7.5, 0.1mM EGTA, 0.1mM Na₃VO₄, 0.1% 2-mercaptoethanol. Use 65–181ng per assay point.
4. **[γ-³³P]ATP:** 2.5 x magnesium acetate/[γ-³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ-³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 2.5µl of 10 x reaction buffer per assay to wells.
2. Add 2.5µl of **poly(Glu, Tyr) (4:1)**.
3. Add **2.5µl (65–181ng) Blk, active**.
4. Add 7.5µl of dH₂O.
5. Add 10µl of diluted [γ-³³P] ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5µl of 3% phosphoric acid.
8. Transfer a 10µl aliquot onto the appropriate area of a **Filtermat A**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

Certificate of Analysis

Blk Sequence Information

<u>Protein</u>	human Blk
<u>Tags</u>	N-terminal 6His
<u>Native sequence</u>	M8 of the recombinant protein is equivalent to M1of human Blk
<u>Accession number</u>	GenBank NM_001715. The recombinant protein contains one residue which is in conflict with NM_001715. This is M287V and is reported in GenBank S76617 and BC007371.

Recombinant Blk amino acid sequence:

```

1 MHHHHHHMGL VSSKKPDKEK PIKEKDKGQW SPLKVSAQDK DAPPLPPLVV FNHLTPPPPD
61 EHLDEDKHFV VALYDYTAMN DRDLQMLKGE KLQVLKGTGD WWLARS�VTG REGYVPSNFV
121 ARVESLEMER WFFRSQGRKE AERQLLAPIN KAGSFLIRES ETNKGAFSLS VKDVTQTQEL
181 IKHYKIRCLD EGGYISPRI TFPSLQALVQ HYSKKGDGLC QRLTLPCVRP APQNPWAQDE
241 WEIPRQSLRL VRKLGSQGFQ EVWMGYKNN MKVAIKTLKE GTMSPEAFGL EANVMKALQH
301 ERLVRLYAVV TKEPIYIVTE YMARGCLLDF LKTDEGSRLS LPRLIDMSAQ IAEGMAYIER
361 MNSIHRDLRA ANILVSEALC CKIADFLGAR IIDSEYTAQE GAKFPIKWT APEAIHFGVFT
421 IKADVVSFGV LLMEVVTYGR VPYPGMSNPE VIRNLERGYR MPRPDTCPE LYRGVIAECW
481 RSRPEERPTF EFLQSVLEDF YTATERQYEL QP

```

Recombinant Blk nucleotide sequence:

```

1 atgcatcacc atcaccatca tatggggctg gtaagtagca aaaagccgga caaggaaaag
61 ccgatcaaag agaaggacaa gggccaatgg agcccctga aggtcagcgc ccaagacaag
121 gacgccccgc cactgccgcc cctgggtgtc ttcaaccacc ttactcctcc accgcccgat
181 gaacacctgg atgaagacaa gcatttcgtg gtggctctgt atgactacac cgctatgaat
241 gatcgggacc tgcagatgct gaagggggag aagctacagg tcctgaaggg aactggagac
301 tgggtggctg ccaggtcact cgtcacagga agagaaggct atgtgccag caactttgtg
361 gcccagagtgg agagcctgga aatggaaagg tggttcttta gatcacaggg tcggaaggag
421 gctgagaggc agcttcttgc tccaatcaac aaggccggct cttttcttat cagagagagt
481 gaaaccaaca aaggtgcctt ctccctgtct gtgaaggatg tcaccacca gggggagctg
541 atcaagcact ataagatccg ctgcctggat gaagggggct actacatctc cccccggatc
601 accttcccct cgctccaggc cctgggtcag cactattcta agaaggggga tggctctatg
661 cagaggctga ccctgccctg tgtgcgcccg gcccgcaga atccctgggc ccaggatgaa
721 tgggagatcc cccggcagtc tctcaggctg gtcaggaaac tcgggtctgg acaattcggc
781 gaagtctgga tgggttacta caaaaacaac atgaagggtg ccattaagac gctgaaggag
841 ggaaccatgt ctccagaagc ctttctgggt gaggccaacg tgatgaagge tctgcagcac
901 gagcggctgg tccgactcta cgcagtgggt accaaggagc ccatctacat tgtcaccgag
961 tacatggcca gaggatgcct gctggatttc ctgaagacag atgaagggag cagattgtca
1021 ctccaaaggc tgattgacat gtcggcgagc attgctgaag ggatggcata cattgagcgc
1081 atgaattcca tccaccgcga cctggcgggc gccaacatcc tgggtgtcta ggccttgtgc
1141 tgcaaaattg ctgattttgg cttggctcga atcatcgaca gtgaatacac ggcccaagag
1201 ggggccaagt tcccatcaa gtggacagcc ccggaagcca tccacttcgg ggtcttcacc
1261 atcaaagcag acgtgtggtc gtttgagatc ctctgatgg aagttgtcac ttatgggcgg
1321 gtgccatacc cagggatgag caaccgccag gtcattccgc acctggagcg cggtaccgc
1381 atgccgcgcc ccgacacctg cccgcccgag ctgtaccgcg gcgtcatcgc cgagtgtgtg
1441 cgcagccggc ccgaggagcg gccaccttc gagttcctgc agtcggtgct ggaggacttc
1501 tacacggcca ccgagcgga gtacgagctg cagccctag

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.